In the Towers Lab we aim to understand the molecular details of host virus interactions particularly with respect to innate immunity. We consider novel therapeutic approaches for viral infection and inflammation and to use viruses to help us understand mammalian cell biology and evolution. We also want to know what is special about pandemic viruses HIV-1(M) and SARS-CoV-2 and how have they adapted to replicate in humans and cause disease.
"How the 'Aplha' Coronavirus Variant Became So Powerful". The Towers and collaborators including Jolly and Krogen lab's work is featured in The New York Times. Carl Zimmer interviewed Prof Greg Towers and Prof Nevan Krogan to discuss how the Alpha Variant evades immune responses.
We are funded by a Senior Biomedical Research Fellowship No 108183 from Wellcome to Professor Greg Towers and a Wellcome collaborative award as well as grants from the Medical Research Council and the National Institute for Health Research.